Inuvo Future Growth
Future criteria checks 1/6
Inuvo is forecast to grow earnings and revenue by 62.4% and 19.6% per annum respectively while EPS is expected to grow by 63.1% per annum.
Key information
62.4%
Earnings growth rate
63.1%
EPS growth rate
| Software earnings growth | 39.6% |
| Revenue growth rate | 19.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 11 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 116 | -3 | N/A | N/A | 1 |
| 12/31/2025 | 106 | -2 | -1 | 1 | 3 |
| 12/31/2024 | 83 | -7 | 1 | 3 | 3 |
| 9/30/2024 | 78 | -8 | -4 | -2 | N/A |
| 6/30/2024 | 81 | -7 | -3 | -1 | N/A |
| 3/31/2024 | 79 | -9 | -2 | -1 | N/A |
| 12/31/2023 | 74 | -10 | -4 | -3 | N/A |
| 9/30/2023 | 70 | -12 | -5 | -3 | N/A |
| 6/30/2023 | 63 | -15 | -7 | -6 | N/A |
| 3/31/2023 | 69 | -14 | -7 | -5 | N/A |
| 12/31/2022 | 76 | -13 | -7 | -6 | N/A |
| 9/30/2022 | 78 | -10 | -5 | -3 | N/A |
| 6/30/2022 | 78 | -8 | -8 | -6 | N/A |
| 3/31/2022 | 68 | -8 | -8 | -6 | N/A |
| 12/31/2021 | 60 | -8 | -7 | -5 | N/A |
| 9/30/2021 | 53 | -7 | -7 | -6 | N/A |
| 6/30/2021 | 45 | -8 | -6 | -5 | N/A |
| 3/31/2021 | 40 | -7 | -10 | -9 | N/A |
| 12/31/2020 | 45 | -7 | -7 | -6 | N/A |
| 9/30/2020 | 50 | -7 | -6 | -5 | N/A |
| 6/30/2020 | 55 | -4 | -8 | -7 | N/A |
| 3/31/2020 | 61 | -5 | -5 | -3 | N/A |
| 12/31/2019 | 62 | -4 | -7 | -5 | N/A |
| 9/30/2019 | 60 | -6 | -8 | -6 | N/A |
| 6/30/2019 | 63 | -8 | -4 | -3 | N/A |
| 3/31/2019 | 68 | -7 | -5 | -4 | N/A |
| 12/31/2018 | 73 | -6 | -4 | -2 | N/A |
| 9/30/2018 | 80 | -3 | 0 | 2 | N/A |
| 6/30/2018 | 84 | -2 | N/A | 2 | N/A |
| 3/31/2018 | 83 | -3 | N/A | 1 | N/A |
| 12/31/2017 | 80 | -3 | N/A | -1 | N/A |
| 9/30/2017 | 75 | -4 | N/A | -2 | N/A |
| 6/30/2017 | 73 | -4 | N/A | -2 | N/A |
| 3/31/2017 | 70 | -3 | N/A | -1 | N/A |
| 12/31/2016 | 72 | -1 | N/A | 1 | N/A |
| 9/30/2016 | 73 | 0 | N/A | 1 | N/A |
| 6/30/2016 | 75 | 1 | N/A | 3 | N/A |
| 3/31/2016 | 76 | 2 | N/A | 8 | N/A |
| 12/31/2015 | 70 | 2 | N/A | 6 | N/A |
| 9/30/2015 | 65 | 2 | N/A | 6 | N/A |
| 6/30/2015 | 59 | 2 | N/A | 5 | N/A |
| 3/31/2015 | 53 | 2 | N/A | 2 | N/A |
| 12/31/2014 | 50 | 2 | N/A | 4 | N/A |
| 9/30/2014 | 46 | 1 | N/A | 3 | N/A |
| 6/30/2014 | 47 | 1 | N/A | 3 | N/A |
| 3/31/2014 | 49 | 1 | N/A | 2 | N/A |
| 12/31/2013 | 55 | 0 | N/A | 2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CD5N is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CD5N is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CD5N is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CD5N's revenue (19.6% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: CD5N's revenue (19.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CD5N's Return on Equity is forecast to be high in 3 years time